Tag: ViiV Healthcare

Tablets for HIV-1 Infection Treatment Got FDA Approval

ViiV Healthcare announced that the US Food and Drug Administration (FDA) approved Dovato, a complete, once-daily, single-tablet regimen of dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg for the ...

Monthly and Daily Treatment of HIV-1 Showed Same Efficacy

Johnson & Johnson’s subsidiary Janssen Pharmaceuticals and ViiV Healthcare have revealed 48 week data from two pivotal Phase III trials showing injections of their long-acting, monthly combination...

ViiV Healthcare unveiled positive results from trial of two-drug HIV regimen

viiv healthcare
ViiV Healthcare announced positive headline results from its global, phase III ATLAS study of a long-acting, injectable two-drug regimen (2DR) for the treatment of HIV.

ViiV Healthcare’s HIV treatment showed positive results in phase III studies

viiv healthcare
The GEMINI studies are part of innovative clinical trial programme for two-drug regimens that seeks to address long-term toxicity concerns of people living with HIV by reducing the number of medicines used in their treatment.

ViiV Healthcare received EU marketing authorisation for its HIV treatment

viiv healthcare
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, announced that the European Commission has granted marketing authorisation for Juluca.

ViiV Healthcare received positive opinion for Juluca in Europe

viiv healthcare
ViiV Healthcare, the global specialist HIV company, announced that the CHMP has issued a Positive Opinion recommending marketing authorisation for Juluca for the treatment of HIV infection.

GlaxoSmithKline launches its HIV drug in China

British pharmaceutical giant GlaxoSmithKline has officially launched its blockbuster triple-therapy HIV drug in China, pricing it lower than in neighboring markets

ViiV Healthcare localizes the manufacturing of dolutegravir in Russia

viiv healthcare
Three registration lots of dolutegravir manufactured at Servier Pharmaceutical Plant in Russia successfully passed stability tests and comparative dissolution kinetics tests